Yahtzee is a Good Friend
Miriam Rocke’s service dog fills several roles in her life
“He’s almost 7, but he still acts like a puppy,” says Miriam Rocke. “He does that ‘I have something in my mouth’ walk when he wants to show off.”
Opportunity for New Patients to Enroll in Palovarotene Study
Please read Clementia's Clinical Program Announcement: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study. Click here.
Celebrating One Year of Making a Difference
The FOP Registry is celebrating one year of making a difference today!
IFOPA's Support of Clinical Trials
A Message about the IFOPA's Support for Clinical Trials
Regeneron's Work in FOP
The International FOP Association is pleased to share the following news from Regeneron Pharmaceuticals
Regeneron is pleased to inform you that anti-Activin A antibody, REGN2477, is now in a clinical trial.
A Remarkable Record of Service – And An Important Transition
Thank you for your commitment!
Still active in the FOP community, Dr. Pignolo has a accepted a new position.
Next Step in Clementia's Clinical Program for FOP
Enrollment information and FAQs
The IFOPA is pleased to share the announcement and new FAQs from Clementia Pharmaceuticals regarding the palovarotene clinical trial.
An Update on FOP Drug Development: News from the FOP Italia Annual Meeting
Summary from the IFOPA Research Committee
The FOP research landscape is evolving at a rapid pace in many wonderful ways. Global efforts to develop therapies for FOP are stronger than ever among academic and biopharmaceutical teams. The IFOPA works continuously to monitor and support these efforts, serve as an advocate for the FOP community, and inform you of progress whenever possible.
Penn Animal Study Findings Announced
FOP Flare-Ups
The IFOPA is pleased to share the press release and editorial from the Perelman School of Medicine at the University of Pennsylvania about their Animal Study Findings on FOP Flare-Ups and Low Oxygen.
